Taxes, tech and China to fuel pharma M&A in 2018, says EY

Repatriated cash coupled with growing competitive threats will leave the market 'ripe' for more life sciences deals, according to a new report.

By Jacob Bell • Jan. 7, 2018

With TiGenix buy and Denali deal, Takeda shows its hand

The Japan-based pharma has been eager to expand its global footprint, and two new agreements should help reinforce its presence in Europe and the U.S.

By Jacob Bell • Jan. 5, 2018

In surprise move, Pfizer hands back IDO1 inhibitor

iTeos Therapeutics has regained rights to its Phase 1 brain cancer drug from Pfizer, and plans to continue oncology development.

By Suzanne Elvidge • Jan. 5, 2018

MacroGenics finds new pharma partner in Roche

After being stung by J&J's recent decision to drop a clinical candidate, Macrogenics has lined up another early-stage collaboration deal. 

By Ned Pagliarulo • Jan. 4, 2018

Pfizer targets harmful proteins in $830M deal

A research collaboration between the big pharma and Arvinas will focus on discovering therapies for disease-causing cellular proteins.

By Jacob Bell • Jan. 4, 2018

Indivior adds to addiction pipeline with Addex deal

The UK biotech takes on another addiction treatment after losing patent protection for its lead drug. 

By Lisa LaMotta • Jan. 3, 2018

Top 10 stories that had pharma execs talking

From CAR-T to potential deals, BioPharma readers dove into these pieces.

By Lisa LaMotta • Jan. 3, 2018

AstraZeneca sells US rights to 4 non-core drugs

Continuing its externalization drive, the British drugmaker stands to receive nearly $50 million for handing over several licenses and NDAs to ANI Pharmaceuticals.

By Jacob Bell • Jan. 2, 2018

Mallinckrodt builds pipeline through $1.2B Sucampo deal

Acquiring Sucampo gives the specialty drugmaker an on-market constipation drug and two Phase 3 candidates — just as sales of its top-seller run into headwinds.  

By Ned Pagliarulo • Dec. 26, 2017

Prescribed Reading: FDA approval spree, tax reform, deals pick up

The agency under Scott Gottlieb has hit a new record for approvals, and the new tax bill has already prompted M&A. 

By Lisa LaMotta • Dec. 22, 2017

Roche drops $1.7B for Ignyta and its lung cancer drug

Interim data from October found objective response rates as high as 78% in NSCLC patients with a type of gene rearrangement who took Ignyta's entrectinib.

By Jacob Bell • Dec. 22, 2017

J&J enters CAR-T field with $350M Legend deal

Legend Biotech burst onto the CAR-T scene at this year's ASCO meeting with impressive early results for its anti-BCMA cell therapy in multiple myeloma.   

By Ned Pagliarulo • Dec. 22, 2017

Biopharma trends to watch in 2018

Several macro trends will continue to shape the industry in the new year.

By Ned Pagliarulo , Lisa LaMotta , Jacob Bell • Dec. 22, 2017

MilliporeSigma tapped by bluebird for manufacturing

For bluebird, the deal is another step toward solidifying a stronger production process for its gene therapies.

By Jacob Bell • Dec. 21, 2017

Biogen, Ionis looking for new SMA drugs following Spinraza's success

A freshly inked deal has the biotechs looking at antisense oligonucleotide drug candidates for the treatment of the rare muscular disease.

By Jacob Bell • Dec. 20, 2017

Millendo snaps up Alizé, expanding endocrinology pipeline

Acquiring Alizé will give Millendo a Phase 2 candidate for Prader-Willi syndrome and a foothold in Europe.

By Suzanne Elvidge • Dec. 20, 2017

Hikma to sell Celltrion's Rituxan biosimilar in Africa, Middle East

The London-based generics company already markets in the MENA region two other copycat biologics developed by Celltrion.

By Lisa LaMotta • Dec. 19, 2017

Boehringer Ingelheim inks CNS deal with Autifony

GSK's spinout has hooked up with big pharma Boehringer Ingelheim in a deal to develop a new approach to schizophrenia.

By Suzanne Elvidge • Dec. 19, 2017

Biotech IPOs show no signs of slowing down in 2018

Roughly 40 drugmakers joined U.S. public exchanges in 2017, reflecting a healthy biotech sector, according to market researchers.

By Jacob Bell • Dec. 18, 2017

Biopharma scores big win in tax overhaul

Congress passed a tax code rewrite this week. Here's a cheat sheet for what it means for biopharma.  

By Lisa LaMotta • Dec. 18, 2017

Prescribed Reading: Year-end M&A, Showdown at ASH

New data from the American Society of Hematology conference has the industry buzzing.

By Lisa LaMotta • Dec. 15, 2017

8 Takeout targets to watch in 2018

While dealmaking was sparse in 2017, it's expected to pick up in 2018. Here are eight companies that have good odds of getting acquired.

By Lisa LaMotta • Dec. 15, 2017

Abzena tapped for preclinical ADC development

The CDMO has entered into an agreement worth more than $5 million with a U.S. biotech.

By Jacob Bell • Dec. 14, 2017

Bristol-Myers Squibb picks up I/O programs from Ono

An exclusive deal adds PGE2 receptor antagonists to Bristol-Myers' immuno-oncology portfolio.

By Suzanne Elvidge • Dec. 14, 2017

Vertex licenses its first drug from CRISPR collaboration

CTX001 is a preclinical, ex vivo therapy that the biotechs are looking to push into Phase 1/2 testing for blood disorders in 2018.

By Jacob Bell • Dec. 13, 2017